LEGOCHEM BIOSCIENCES
Lego Chem Bioscience , a company created by people with dreams and enthusiasm for global new drug development, will open up new horizons in Korean new drug development based on systematic drug development system and core technology.
LEGOCHEM BIOSCIENCES
Industry:
Biotechnology Health Care
Address:
Daejeon, Taejon-jikhalsi, South Korea
Country:
South Korea
Website Url:
http://www.legochembio.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Apache Global Site Tag Mobile Non Scaleable Content
Similar Organizations
NeuPharma
NeuPharma is a biotech company dedicated to research and development of innovative medicines.
Current Employees Featured
Founder
Official Site Inspections
http://www.legochembio.com Semrush global rank: 7.74 M Semrush visits lastest month: 437
- Host name: ec2-43-203-36-236.ap-northeast-2.compute.amazonaws.com
- IP address: 43.203.36.236
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "LegoChem Biosciences"
LegoChem Biosciences - LinkedIn
LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to the discovery, development, and commercialization of innovative medicines by leveraging our chemistry...See details»
WuXi XDC and LegoChem Biosciences Signed Memorandum of …
Jun 10, 2021 · LegoChem Biosciences (LCB) is a clinical-stage biopharmaceutical company focusing on the development of next-generation novel therapeutics utilizing its proprietary …See details»
LegoChem Biosciences - Craft
Oct 28, 2024 · LegoChem Biosciences ₩34.15 b in annual revenue in FY 2023. See insights on LegoChem Biosciences including office locations, competitors, revenue, financials, executives, …See details»
Leadership > about us > LigaChem Biosciences
To become a global leader of new drug development by leveraging our experience and expertiseSee details»
SOTIO Expands its Antibody-Drug Conjugate Pipeline with E...
Nov 16, 2021 · LegoChem Biosciences (LCB, KOSDAQ: 141080) is a clinical-stage biopharmaceutical company focusing on the development of next-generation novel …See details»
LegoChemBio - VentureRadar
Website: http://www.legochembio.com/ Develops innovative medicines using medicinal chemistry expertise to create targeted and potent biologics for unmet medical needs in antibiotics, anti …See details»
LegoChemBio Signs License Agreement to Acquire First-in-class
Feb 14, 2023 · DAEJEON, South Korea– (BUSINESS WIRE)– LegoChem Biosciences Inc. (KOSDAQ:141080) (hereinafter “LegoChemBio”) announced on February 13, 2023 a license …See details»
Press Release > investors > LigaChem Biosciences
Mar 9, 2023 · LegoChem Biosciences (LCB, KOSDAQ: 141080) is a clinical-stage biopharmaceutical company focusing on the development of next-generation novel …See details»
LegoChem Biosciences Selects BostonGene as …
Nov 7, 2023 · LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080), is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation novel therapeutics utilizing its...See details»
LegoChem Biosciences Selects BostonGene as Genomic Partner
Nov 7, 2023 · LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080), is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation …See details»
LegoChem Biosciences, Inc. | Working Group for New TB Drugs
Project Leader of Development Center LegoChem Biosciences, Inc. 8-26 Munpyeongseo-ro, Daedeok-gu Daejeon, 306-220, Korea (Mobile) +82-10-7724-2913, (Fax) +82-42-861-0689.See details»
LegoChem Biosciences and Amgen Enter into a Multi-Target …
Dec 23, 2022 · Under the terms of the agreement, LCB is eligible to receive up to USD 1.25 billion including upfront, development and commercial milestone payments, and is also eligible for …See details»
Innovation Centers | Johnson & Johnson Innovation
LegoChem Biosciences to receive up to potentially USD1.7 billion in total, including an upfront payment and option exercise feeSee details»
Press Release > investors > LigaChem Biosciences
Jan 2, 2024 · LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC. LegoChem Biosciences to receive up to potentially USD1.7 billion in total, including …See details»
LegoChem strikes historic $1.7B license deal with Janssen
Dec 26, 2023 · LegoChem Biosciences, a Korean biopharmaceutical company, signed a landmark $1.7 billion licensing deal with Janssen Biotech for its solid cancer treatment …See details»
Samsung Biologics partners with LegoChem Biosciences for ADC ...
Feb 7, 2024 · LegoChem Biosciences aims to submit an Investigational New Drug application to the U.S. FDA in the first half of 2025, with non-clinical data showing promising efficacy results. …See details»
Cellectar Announces a Co-Development and Commercialization
Jul 12, 2021 · Under the agreement, the two companies have the option to jointly develop three new small molecule PDCs utilizing Cellectar’s proprietary drug targeting platform, phospholipid …See details»
LegoChem, Amgen partner to develop antibody drug conjugates
Dec 26, 2022 · LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). Intravenous …See details»
LegoChem Biosciences and Glycotope Announce Research
Jul 12, 2022 · Seoul, South Korea, and Berlin, Germany - (July 12, 2022) – LegoChem Biosciences Inc. (LCB) and Glycotope GmbH (Glycotope) have signed a Research …See details»
Elthera: License agreement with Korean LegoChemBio for cancer …
Feb 13, 2023 · LegoChem Biosciences Inc. (141080KS, hereinafter “LegoChemBio”) announced a license agreement with Elthera AG, a biotechnology company in Switzerland, to develop and …See details»